University of Nebraska Medical Center
University of Nebraska Medical Center

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

CureVac

  • Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat
  • Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone
  • Avian influenza is latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK

Continue reading

Fair Use Notice

UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.

twitter facebook bluesky email print

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.